The potent TGF-β antagonist Norrin as a new drug for the treatment of fibrotic diseases and cancer
Human Norrin protein has been originally identified in the art as being a crucial
factor in the development of Norrie disease and is thought to be primarily involved in the Wnt signaling pathway. In the present invention, Norrin is being identified for the first time as a potent TGF-β antagonist/inhibitor. Furthermore, it has surprisingly been found herein that Norrin can be used in the treatment of diseases associated with an increased TGF-β activity level, such as fibrotic diseases and proliferative diseases, resp. cancer.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Webb captures top of iconic horsehead nebula in unprecedented detail
NASA’s James Webb Space Telescope has captured the sharpest infrared images to date of a zoomed-in portion of one of the most distinctive objects in our skies, the Horsehead Nebula….
Cost-effective, high-capacity, and cyclable lithium-ion battery cathodes
Charge-recharge cycling of lithium-superrich iron oxide, a cost-effective and high-capacity cathode for new-generation lithium-ion batteries, can be greatly improved by doping with readily available mineral elements. The energy capacity and…
Novel genetic plant regeneration approach
…without the application of phytohormones. Researchers develop a novel plant regeneration approach by modulating the expression of genes that control plant cell differentiation. For ages now, plants have been the…